Home/Filings/4/0001012975-14-000787
4//SEC Filing

MEI Pharma, Inc. 4

Accession 0001012975-14-000787

$LITSCIK 0001262104operating

Filed

Dec 9, 7:00 PM ET

Accepted

Dec 10, 7:26 PM ET

Size

19.3 KB

Accession

0001012975-14-000787

Insider Transaction Report

Form 4
Period: 2014-12-08
Transactions
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
Transactions
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
Lathi Vijay K
10% Owner
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
HUNT RONALD
10% Owner
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
Transactions
  • Sale

    Common Stock

    2014-12-08$6.05/sh9,004$54,4951,671,471 total
  • Sale

    Common Stock

    2014-12-09$6.01/sh70,081$421,0821,601,390 total
Footnotes (3)
  • [F1]The price reported in Column 4 is a weighted average price (net of commissions). These shares were sold in multiple transactions at prices ranging from $6.00 to $6.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  • [F2]Represents shares directly beneficially owned by New Leaf Ventures II, L.P. ("NLV II"). New Leaf Venture Associates II, L.P. ("NLV Associates") is the general partner of NLV II and New Leaf Venture Management II, L.L.C. ("NLV Management") is the general partner of NLV Associates. Philippe O. Chambon, Jeani Delagardelle, Ronald Hunt, Vijay Lathi, and Liam Ratcliffe are the individual managers of NLV Management (the "Individual Managers"). NLV Associates and NLV Management disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein. As one of five individual managers, each of the Individual Managers disclaims beneficial ownership over the shares reported herein, and in all events disclaims pecuniary interest except to the extent of his economic interest.
  • [F3]The price reported in Column 4 is a weighted average price (net of commissions). These shares were sold in multiple transactions at prices ranging from $6.00 to $6.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Issuer

MEI Pharma, Inc.

CIK 0001262104

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001262104

Filing Metadata

Form type
4
Filed
Dec 9, 7:00 PM ET
Accepted
Dec 10, 7:26 PM ET
Size
19.3 KB